Kasperczak Michał, Kołodziejczak-Guglas Iga, Kasperczak Filip, Wiznerowicz Maciej, Antczak Andrzej
Department of Urology, J. Struś Hospital in Poznań, Szwajcarska 3, 61-285 Poznan, Poland.
International Institute for Molecular Oncology, 60-203 Poznań, Poland.
Int J Mol Sci. 2025 Jun 30;26(13):6296. doi: 10.3390/ijms26136296.
Clear cell renal cell carcinoma (ccRCC) is a significant global cancer, particularly impacting individuals in Western countries. Despite that, the molecular mechanisms driving renal cell carcinoma progression remain poorly understood, highlighting the need to investigate these mechanisms and identify novel therapeutic targets. Literature evidence suggests that elongation factor Tu GTP binding domain containing 2 (EFTUD2) and prominin (PROM1) gene expression have significant diagnostic potential in early tumor detection, potentially reflecting the trends in progression, and may become a novel therapeutic target. Therefore, this study aimed to evaluate EFTUD2 and PROM1 protein expression on clinical characteristics of ccRCC patients, especially overall and progression-free survival. To achieve that goal, we have combined publicly available liquid chromatography-mass spectrometry (LC-MS/MS) protein expression data with a comprehensive literature review to identify key protein markers for further study and immunohistochemical (IHC) analysis. Our findings highlight the importance of considering protein expression heterogeneity within tumors. The significant variation in EFTUD2 expression, its association with PFS, and its intricate connections with the mRNA splicing machinery underscore the need for a more nuanced understanding of its role in ccRCC. Similarly, the downregulation of PROM1 and its potential effects on cell surface interactions warrant further exploration. Future studies should focus on elucidating the mechanisms underlying these observations, exploring their potential as therapeutic targets, and investigating the specific pathways affected by their dysregulation.
透明细胞肾细胞癌（ccRCC）是一种在全球范围内具有重要影响的癌症，尤其对西方国家的人群影响较大。尽管如此，驱动肾细胞癌进展的分子机制仍知之甚少，这凸显了研究这些机制并确定新治疗靶点的必要性。文献证据表明，含延伸因子Tu GTP结合结构域2（EFTUD2）和prominin（PROM1）的基因表达在早期肿瘤检测中具有显著的诊断潜力，可能反映疾病进展趋势，并且可能成为新的治疗靶点。因此，本研究旨在评估EFTUD2和PROM1蛋白表达对ccRCC患者临床特征的影响，特别是对总生存期和无进展生存期的影响。为实现这一目标，我们将公开可用的液相色谱-质谱联用（LC-MS/MS）蛋白表达数据与全面的文献综述相结合，以确定进一步研究和免疫组织化学（IHC）分析的关键蛋白标志物。我们的研究结果突出了考虑肿瘤内蛋白表达异质性的重要性。EFTUD2表达的显著差异、其与无进展生存期的关联以及与mRNA剪接机制的复杂联系，都强调了更细致地了解其在ccRCC中作用的必要性。同样，PROM1的下调及其对细胞表面相互作用的潜在影响值得进一步探索。未来的研究应集中于阐明这些观察结果背后的机制，探索它们作为治疗靶点的潜力，并研究其失调所影响的具体途径。
